BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases » Page 14

Curi Bio and Cook MyoSite Announce Strategic Partnership

By Leave a Comment

Curi Bio and Cook MyoSite Announce Strategic Scientific Collaboration to Advance Translational Human Muscle Disease Models

SEATTLE & PITTSBURGH — Curi Bio, the global leader in human 3D engineered tissue platforms, and Cook MyoSite, a pioneer in the development of skeletal muscle-based therapies, today announced a strategic partnership to develop advanced, predictive human engineered tissue models aimed at addressing muscle-related diseases and metabolic disorders, including obesity and diabetes. [Read more…]

RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing

By Leave a Comment

FREDERICK, MD., (April 29, 2025) —RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease. [Read more…]

I Peace Launches Personalized iPS Cell Services and Longevity Treatment in the U.S. – Age-Reversed Stem Cell Technology Now Available to the Public –

By Leave a Comment

Palo Alto, CA – I Peace, Inc., a global pioneer in iPSC (induced pluripotent stem cell) technology, proudly announces the launch of its personalized iPS cell production and longevity-focused rejuvenation therapies in the United States.

I Peace CEO Koji Tanabe spoke at the “Unlimited Health Conference,” a part of the Vitalist Bay, the biggest longevity event in the world, which is held in Berkeley, California. The event was held on April 5. [Read more…]

Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies

By Leave a Comment

Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases. Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages, making them a promising option for the treatment of blood cancers, solid tumors, and autoimmune diseases. Cellistic’s Echo™-NK platform provides drug developers with a commercially viable solution for an Off-the-Shelf NK cell therapy. [Read more…]

Sernova Advances Cell Pouch Type I Diabetes Trial; Will Test iPSC-Derived Clusters Next

By Leave a Comment

  • Current Trial (Cohorts A–C): Sernova’s current cohorts are focused on testing the safety and tolerability of transplanting donor islets (from cadaveric pancreases) into Sernova’s Cell Pouch device in T1D patients.
  • Future Direction (Post-Cohort C): Next, Sernova plans to launch a new clinical trial using iPSC-derived islet-like clusters, instead of relying on donor islets. This will be in collaboration with Evotec, a leading iPSC company.
  • Why iPSCs Matter: iPSC-derived islet-like clusters offer a renewable, potentially unlimited cell source for treating T1D, overcoming the limitations of donor availability. This aligns with Sernova’s goal of developing a scalable and widely accessible solution.

[Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0